Dazonay 175+43,75+200 mg filmovertrukne tabletter Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

dazonay 175+43,75+200 mg filmovertrukne tabletter

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 175+43,75+200 mg

Sastravi 125+31,25+200 mg filmovertrukne tabletter Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

sastravi 125+31,25+200 mg filmovertrukne tabletter

actavis group ptc ehf. - carbidopamonohydrat, entacapon, levodopa - filmovertrukne tabletter - 125+31,25+200 mg

Sastravi 175+43,75+200 mg filmovertrukne tabletter Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

sastravi 175+43,75+200 mg filmovertrukne tabletter

actavis group ptc ehf. - carbidopamonohydrat, entacapon, levodopa - filmovertrukne tabletter - 175+43,75+200 mg

Sastravi 200+50+200 mg filmovertrukne tabletter Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

sastravi 200+50+200 mg filmovertrukne tabletter

actavis group ptc ehf. - carbidopamonohydrat, entacapon, levodopa - filmovertrukne tabletter - 200+50+200 mg

Apixaban Accord Unione Europea - danese - EMA (European Medicines Agency)

apixaban accord

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antitrombotiske midler - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. forebyggelse af apopleksi og systemisk emboli hos voksne patienter med non-valvulær atrieflimmer (nvaf), med en eller flere risikofaktorer, som før slagtilfælde eller forbigående iskæmiske anfald (tia); alder ≥ 75 år; højt blodtryk; diabetes mellitus; symptomatisk hjertesvigt (nyha klasse ≥ ii). behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe hos voksne (se afsnit 4. 4 for haemodynamically ustabile pe patienter). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe hos voksne (se afsnit 4. 4 for haemodynamically ustabile pe patienter).

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Unione Europea - danese - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for yderligere oplysninger henvises der til afsnit 5.

Eperzan Unione Europea - danese - EMA (European Medicines Agency)

eperzan

glaxosmithkline trading services limited - albiglutide - diabetes mellitus, type 2 - narkotika anvendt i diabetes - eperzan er indiceret til behandling af type 2-diabetes mellitus hos voksne til forbedring af glykæmisk kontrol som:monotherapywhen diæt og motion alene ikke giver tilstrækkelig glykæmisk kontrol hos patienter, for hvem brug af metformin anses for uhensigtsmæssig på grund af kontraindikationer eller intolerance. add-on kombination therapyin kombination med andre glukose-sænkende lægemidler, herunder basal insulin, når disse sammen med diæt og motion, ikke giver tilstrækkelig glykæmisk kontrol (se afsnit 4. 4 og 5. 1 for tilgængelige data på forskellige kombinationer).

Infanrix Penta Unione Europea - danese - EMA (European Medicines Agency)

infanrix penta

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vacciner - infanrix penta er indiceret til primær- og boostervaccination af spædbørn mod difteri, stivkrampe, pertussis, hepatitis b og poliomyelitis..